Keywords:
Oncologic Imaging, Contrast agents, Liver, Oncology, MR, Contrast agent-intravenous, Molecular imaging, Treatment effects, Cancer, Metastases, Retrospective, Case-control study, Performed at one institution
Authors:
S. Matsushima1, S. Murata1, Y. Sato1, H. Onaya2, H. Yamaura1, M. kato1, T. Hasegawa1, H. Ogura1, Y. Inaba1; 1Nagoya/JP, 2Tokyo/JP
DOI:
10.26044/ecr2020/C-01196
Purpose
Background
Gadoxeticacid-enhanced magnetic resonance imaging (MRI) is a standard modality for assessing colorectal liver metastases (CLM) since the hepatobiliary phase (HBP) offers an excellent lesion to liver contrast and increases the lesion detection rate for assessing the resectabilityof liver metastases [1]. The relative liver enhancement (RLE) value on HBP is potentially useful for the MRI assessment of heterogeneous liver function [2-4]. The value of HBP relative tumor enhancement (RTE) is a potential useful biomarker for predicting early treatment response based on tumor heterogeneityin CLMs[5].
Purpose
Texture analysis was a technique used for the quantification of image texture. Texture analysis presumes the theoretical background that heterogeneity of tumor acts as a worse factor for prognosis and treatment outcome[6].The RTE images were quantitative images using by gadoxeticacid disodium-MRI for CLM.
The aim of this study was to evaluate a correlation between histomorphometryand relative tumor enhancement images by the texture analysis in CLM.